Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Sep 03, 2019 8:07pm
59 Views
Post# 30092557

RE:RE:It is fun to read ...

RE:RE:It is fun to read ...Hold it for a bit guys with name calling and let us focus on objective merits. Meir, in his latest news release does have apoint. Opiods are creating M&A huge alues in the market place. The market is trowing the water basket with the babies, We do not know what is available or what is worth looking to buy or not but the deals are there for sure. Mug you also said it that the whole pharma sphere in depressed. As such it presents bargains. How long these deal will last we do not know, what I do know that they will not last forever and you cannot ever be smart enough to pick a bottom or you will miss out.  So, JG forget fightinh with Meir rise above and focus, work hard, find a good team,and get off your bu..t and get us a deal that we have being waiting for over five Years. Yes Mr. JG you have dropped the ball in the past few times but please do not sc re w this one and redeem. As for Meir, yes he has taken the opportunity to jab but that is personal and between the two of them. On the other end Mr. Meir, hyou too should be looking for deals and sugest it to JG rather than wait and be a critic. Team work and success is all I want from you two Titans. Get GUD to $10 and I will buy you lunch. Now and in the near future is the time to bottom fish. But with regrets I have doubts and I am triming my holding in GUD
Bullboard Posts